Metsera (NASDAQ:MTSR) Shares Gap Up After Analyst Upgrade

Metsera, Inc. (NASDAQ:MTSR)’s share price gapped up prior to trading on Tuesday after Guggenheim raised their price target on the stock from $56.00 to $62.00. The stock had previously closed at $30.39, but opened at $32.35. Guggenheim currently has a buy rating on the stock. Metsera shares last traded at $37.42, with a volume of 959,269 shares traded.

Several other research firms also recently issued reports on MTSR. Cantor Fitzgerald started coverage on Metsera in a report on Tuesday, February 25th. They set an “overweight” rating on the stock. Evercore ISI started coverage on Metsera in a report on Tuesday, February 25th. They issued an “outperform” rating for the company. Finally, Bank of America assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $38.00 target price on the stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MTSR. Rhumbline Advisers bought a new stake in Metsera in the 1st quarter valued at about $520,000. Strs Ohio purchased a new position in shares of Metsera in the first quarter valued at $76,000. Siren L.L.C. purchased a new position in shares of Metsera during the 1st quarter valued at $4,083,000. Woodline Partners LP purchased a new position in Metsera in the 1st quarter worth approximately $8,172,000. Finally, Goldman Sachs Group Inc. bought a new position in Metsera during the first quarter valued at approximately $568,000.

Metsera Price Performance

The stock’s fifty day moving average price is $23.12.

Metsera (NASDAQ:MTSR) last announced its quarterly earnings results on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.